A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin

Inclusion Criteria: * Patients must have a diagnosis of Hepatocellular carcinoma confirmed by at least one of the following: a) histological confirmation; b) imaging results consistent with cirrhosis and at least one solid liver lesion of \>2cm with early enhancement and delayed washout (AASLD criteria for diagnosis of HCC); c) Alpha fetoprotein level \>400ng/mL and evidence of at least one solid liver lesion \>2cm, regardless of specific imaging characteristics on MRI. * Tumor not suitable for resection at the time of study entry. (Transplant eligible patients are allowed) * Age ≥ 18 years. * Performance status ECOG PS 0-1 (Eastern Cooperative Oncology Group Performance Status). * Child Pugh Score A only * Adequate organ and marrow function as defined below: * leukocytes ≥ 3,000/mcL (Measurement and Calibration Lab) * absolute neutrophil count ≥ 1,500/mcL * platelets ≥ 75,000/mcl * total bilirubin ≤ 3.0 * AST (Aspartate Aminotransferase)(SGOT)/ALT (Alanine Aminotransferase)(SPGT) ≤ 5 X institutional upper limit of normal * creatinine ≤ 2.0 * INR (International Normalized Ratio) ≤ 1.8 * Albumin ≥ 2.8 * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform…